RUNX1：心血管疾病治疗的新靶点。

British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular & Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.

Max Planck Institute for Heart and Lung Research, Ludwigstr. 43, 61231 Bad Nauheim, Germany.

Cardiovasc Res. 2020 Jul 1;116(8):1410-1423. doi: 10.1093/cvr/cvaa034.

Runt-related transcription factor-1 (RUNX1), also known as acute myeloid leukaemia 1 protein (AML1), is a member of the core-binding factor family of transcription factors which modulate cell proliferation, differentiation, and survival in multiple systems. It is a master-regulator transcription factor, which has been implicated in diverse signalling pathways and cellular mechanisms during normal development and disease. RUNX1 is best characterized for its indispensable role for definitive haematopoiesis and its involvement in haematological malignancies. However, more recently RUNX1 has been identified as a key regulator of adverse cardiac remodelling following myocardial infarction. This review discusses the role RUNX1 plays in the heart and highlights its therapeutic potential as a target to limit the progression of adverse cardiac remodelling and heart failure.

runt 相关转录因子-1（RUNX1），也称为急性髓系白血病 1 蛋白（AML1），是调节细胞增殖、分化和存活的核心结合因子家族转录因子的成员，在多个系统中。它是一种主调控转录因子，在正常发育和疾病过程中的多种信号通路和细胞机制中都有涉及。RUNX1 最显著的特征是对确定性造血的不可或缺作用及其在血液恶性肿瘤中的参与。然而，最近发现 RUNX1 是心肌梗死后心脏不良重构的关键调节因子。本综述讨论了 RUNX1 在心脏中的作用，并强调了其作为限制心脏不良重构和心力衰竭进展的治疗靶点的潜在价值。